Standard & Poor's Ratings Services said its ratings on Takeda Pharmaceutical Co Ltd would remain unaffected by the company's plan to buy Amgen KK, the Japanese unit of US biotechnology firm Amgen Inc
Discuss Add this link to...Bury Add to:
| Bookmarks
Comments